About the PEGASUS-2 project
PEGASUS-2 acronym is for «PErsonalized Genomics for prenatal Abnormalities Screening USing maternal blood : Towards First Tier Screening and Beyond»
The discovery that DNA of fetal origin is present in maternal blood during pregnancy has led to a new genomics-based maternal blood test called non-invasive prenatal screening (NIPS), which is very reliable at screening for Down syndrome. Currently, public healthcare systems pay for this expensive NIPS test only as a second-tier screening for women who have first screened positive on less costly and less accurate biochemical and ultrasound tests. Hence, only after an initial screen has delivered a positive result is NIPS currently used to help women participating in prenatal screening programs avoid a diagnostic amniocentesis...
